ワシントンにおける卵巣がんの臨床試験
ワシントン内の拠点で、卵巣がんに関する38件の研究が参加者を募集しています。
ワシントン内の都市
公式研究テキスト（英語）
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Swedish Cancer Institute-Edmonds, Edmonds
- Swedish Cancer Institute-Issaquah, Issaquah
- Providence Regional Cancer System-Lacey, Lacey
- 他4件
被験者募集中第2相
全年齢 · 全性別 · 2026/10/02更新 · NCT05564377The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- University of Washington, Fred Hutchinson Cancer Center, Seattle
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/10/02更新 · NCT04585750Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study
- University of Washington, Seattle
被験者募集中
18歳以上 · 女性 · 2026/09/29更新 · NCT05287451A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- Providence Sacred Heart Medical Center & Children'S Hospital /ID# 274585, Spokane
被験者募集中第2相
18歳以上 · 女性 · 2026/09/29更新 · NCT06890338Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- Fred Hutchinson Cancer Center, Seattle
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/25更新 · NCT04981119A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
- Seattle Cancer Care Alliance at South Lake Union - G3630, Seattle
被験者募集中第1/2相
18歳以上 · 女性 · 2026/09/24更新 · NCT04590326A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
- Virginia Mason Hospital and Medical Center /ID# 277259, Seattle
被験者募集中第2相
18歳以上 · 女性 · 2026/09/22更新 · NCT07059845A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Swedish Cancer Institute - Edmonds, Edmonds
- Swedish Medical Center, Seattle
- Fred Hutchinson Cancer Center, Seattle
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07213804IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence
- Fred Hutch/University of Washington Cancer Consortium, Seattle
被験者募集中第2相
18歳以上 · 女性 · 2026/09/21更新 · NCT07495124Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- University of Washington Fred Hutchinson, Seattle
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/21更新 · NCT05983432Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
- Providence Sacred Heart Medical Center & Children's Hospital, Spokane
被験者募集中第3相
18歳以上 · 女性 · 2026/09/15更新 · NCT06915025Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Virginia Mason Medical Center, Seattle
- Fred Hutchinson Cancer Center, Seattle
被験者募集中第3相
18歳以上 · 女性 · 2026/09/15更新 · NCT07214779FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- Providence Sacred Heart Medical Center, Spokane
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/14更新 · NCT06303505Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
- Swedish Cancer Institute, Seattle
被験者募集中第2相
18歳以上 · 女性 · 2026/09/14更新 · NCT06787612The Vanguard Study: Testing a New Way to Screen for Cancer
- Madigan Army Medical Center, Tacoma
被験者募集中健康なボランティア歓迎
45歳〜75歳 · 全性別 · 2026/09/02更新 · NCT06995898Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- Providence Sacred Heart Medical Center & Children's Hospital, Spokane
被験者募集中第3相
18歳以上 · 女性 · 2026/08/26更新 · NCT05281471A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- Providence Regional Cancer System-Aberdeen, Aberdeen
- PeaceHealth Saint Joseph Medical Center, Bellingham
- Providence Regional Cancer System-Centralia, Centralia
- 他19件
被験者募集中
35歳〜50歳 · 女性 · 2026/08/07更新 · NCT04251052Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- Providence Regional Cancer System-Aberdeen, Aberdeen
- PeaceHealth Saint Joseph Medical Center, Bellingham
- Providence Regional Cancer System-Centralia, Centralia
- 他20件
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/07更新 · NCT06580314Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
- Fred Hutchinson Cancer Center, Seattle
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/05更新 · NCT07444814A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Wenatchee Valley Hospital and Clinics, Wenatchee
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/05更新 · NCT06330064Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Swedish Cancer Institute, Seattle
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/04更新 · NCT05579366Clinical Pre-screening Protocol for Ovarian Cancer
- Swedish Center for Research and Innovation, Seattle
被験者募集中観察研究
18歳以上 · 女性 · 2026/07/30更新 · NCT03877796A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- University of Washington - Seattle Cancer Care Alliance, Seattle
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/07/28更新 · NCT06161025A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- University of Washington School of Medicine, Seattle
被験者募集中第2相
8歳以上 · 全性別 · 2026/07/27更新 · NCT05503797A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Northwest Medical Specialities. PLLC, Bonney Lake
- Swedish Cancer Institute - Edmonds Campus, Edmonds
- Swedish Cancer Institute Edmonds Campus, Edmonds
- 他9件
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/06更新 · NCT04389632A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Fred Hutchinson Cancer Center, Seattle
- Summit Cancer Centers, Spokane
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/06/29更新 · NCT05377996Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
- Fred Hutchinson Cancer Center, Seattle
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/06/23更新 · NCT06993844Adapted Helping Ovarian Cancer Patients Cope Intervention to Address Burnout for Gynecologic Oncology Clinicians
- Fred Hutch/University of Washington Cancer Consortium, Seattle
被験者募集中健康なボランティア歓迎
18歳以上 · 全性別 · 2026/06/17更新 · NCT07282158A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
- Fred Hutchinson Cancer Center, Seattle
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/06/12更新 · NCT06051695DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- USA09-0, Puyallup
- USA07-0, Spokane
被験者募集中第2相
18歳以上 · 全性別 · 2026/05/22更新 · NCT06953089ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- Fred Hutchinson Cancer Center, Seattle
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/05/13更新 · NCT03686124Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study
- Fred Hutch/University of Washington Cancer Consortium, Seattle
被験者募集中観察研究
全年齢 · 全性別 · 2026/04/17更新 · NCT06295965TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
- University of Washington, Seattle
被験者募集中
25歳〜50歳 · 女性 · 2026/04/06更新 · NCT04294927Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
- Northwest Medical Specialties, PLLC, Tacoma
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/04/01更新 · NCT05735080A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
- Fred Hutchinson Cancer Center, Seattle
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/03/27更新 · NCT06395519A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
- Fred Hutchinson Cancer Center, Seattle
被験者募集中第1相
18歳以上 · 全性別 · 2026/02/13更新 · NCT06778863SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Seattle
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer
- The Swedish Hospital, Seattle
被験者募集中観察研究
30歳以上 · 女性 · 2025/09/16更新 · NCT04794322ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。